[Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide]. 
Three cases of secondary acute myeloid leukemia (AML) that developed after long term treatment with oral etoposide were reported.  Case 1 was a 72-year-old male in whom small cell lung cancer was diagnosed in January 1987.  He developed AML (M4) in February 1993 after long-term treatment with oral etoposide (total dose 14,650 mg) t(9; 11) (p21; q23) with rearrangement of MLL genes was recognized.  Case 2 was a 68-year-old female non-Hodgkin's lymphoma (NHL) was diagnosed in February 1989.  AML (M4Eo) with inv(16) (p13q22) developed in March 1994 after long-term treatment with oral etoposide (total dose 5,100 mg).  Case 3 was a 39-year-old male in whom NHL was diagnosed in January 1991.  He developed AML(M2) with t(11; 19) (q23; p13) in May 1994 after long-term treatment with oral etoposide (total dose 20,450 mg).  These three cases suggest that long-term treatment with oral etoposide may be associated with a risk of developing a secondary AML in patient with malignancies.